|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
We investigated whether vitamin D receptor (<i>VDR</i>) polymorphisms were associated with cancer biomarkers, i.e., E-cadherin, matrix metallopeptidase 9 (MMP9), interferon β (IFNβ), soluble intercellular adhesion molecule-1 (s-ICAM-1), soluble vascular cell adhesion molecule-1 (s-VCAM-1), tumor necrosis factorα (TNFα), interleukin 6 (IL6), plasminogen activator inhibitor-1(PAI-1), and human high sensitivity C-reactive protein (hs-CRP), among breast cancer survivors who received vitamin D3 supplementation.
|
31167402 |
2019 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer.
|
26716512 |
2016 |
|
Malignant neoplasm of breast
|
0.560 |
AlteredExpression
|
disease |
BEFREE |
In addition, cancer-associated fibroblasts (CAF) isolated from a breast cancer patient were also able to express TRAIL and IFN-β upon DNA and RNA stimulation.
|
27077807 |
2016 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
CAFs not expressing the interferon response genes also promoted the growth of the MCF-7 breast cancer cell line but this phenotype was independent of the type one fibroblast interferon ligand.
|
25884794 |
2015 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
An in vivo assay performed using MDA-MB-231/luc breast cancer mammary fat pad xenografts in immunodeficient mice resulted in 50% reduced tumor growth and increased long-term survival in HB1.F3.CD and HB1.F3.CD.IFN-β plus 5-FC treated mice relative to controls.
|
24141111 |
2014 |
|
Malignant neoplasm of breast
|
0.560 |
Biomarker
|
disease |
BEFREE |
These results indicate that a combination treatment of UCMS-IFN-beta cells and 5-FU is a potentially effective therapeutic procedure for breast cancer.
|
18608205 |
2008 |
|
Malignant neoplasm of breast
|
0.560 |
Therapeutic
|
disease |
CTD_human |
These results indicate that a combination treatment of UCMS-IFN-beta cells and 5-FU is a potentially effective therapeutic procedure for breast cancer.
|
18608205 |
2008 |
|
Malignant neoplasm of breast
|
0.560 |
GeneticVariation
|
disease |
UNIPROT |
|
|
|
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long-term follow-up studies of DMTs in MS have generally shown that the short-term effects in clinical trials are maintained for up to 21 years, e.g. in the case of interferon beta-1b.
|
30610426 |
2020 |
|
Multiple Sclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Fingolimod in paediatric MS was associated with consistent control of disease activity versus IFN β-1a (including treatment-naïve and younger patients) and resulted in less disability progression for up to 2 years.
|
31467033 |
2020 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fourteen percent of all patients were treated with chronic immunosuppressants, 38% of patients with NMO underwent plasmapheresis, and 50% of patients with MS were treated with interferon-β.
|
31732227 |
2020 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferon-beta (IFN-β) has emerged as one of the most common drugs for the treatment of RR-MS patients.
|
31606972 |
2020 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Episodic relapses of the disease which lead to brain lesions and irreversible neurological dysfunctions could be decreased by the interferon-beta (IFN-β) therapy in most of the MS patients.
|
31649263 |
2020 |
|
Hepatitis B
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The IFN-β-Luc expression and level of hepatitis B virus surface Antigen (HBsAg) showed that DDX3 mediated by the 5-HT<sub>7</sub> agonist (AS-19) increased IFN-β expression and inhibited HBV replication.
|
31172579 |
2019 |
|
Hepatitis B
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of miR-3613-3p decreased relative expressions of IFN-α and IFN-β, HBV DNA copies, and increased the hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) levels, whereas miR-3613-3p overexpression reversed these changes in vitro and in vivo.
|
31201869 |
2019 |
|
Hepatitis B
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Interferon β promoter stimulator 1 polymorphisms (IPS-1) regulate interferon (IFN) mediated viral clearance in hepatitis B virus (HBV) infection.
|
30930359 |
2019 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Melanoma differentiation associated gene-7 (mda-7) selectively promotes these effects in cancer cells. mda-7 was identified more than two decades ago by subtraction hybridization showing elevated expression during induction of terminal differentiation of metastatic melanoma cells following treatment with recombinant fibroblast interferon and mezerein (a PKC activating agent).
|
31356866 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to elucidate whether antitumor effects could be augmented by the combination of TMZ and IFN‑β in malignant melanoma.
|
30864696 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results illustrate that engineered hNSCs prevented malignant melanoma cells from proliferating in the presence of the prodrug, and the form that secreted IFN-β intervened in the EMT process and melanoma metastasis.
|
30213181 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The precise mechanisms underlying the tumor-suppressive effects of IFN-β on melanoma are not yet completely understood.
|
31070806 |
2019 |
|
Multiple Sclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate the prognostic value of select clinical scores in interferon beta-1b (IFNβ-1b) treated MS patients.
|
31793659 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Interferonbeta-1b (IFNβ-1b) developed as therapeutic protein for the treatment of multiple sclerosis (MS).
|
31522451 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The objective of our study was to evaluate the relationship of percentage of annualized brain volume loss (aBVL) and no evidence of disease activity (NEDA) in multiple sclerosis (MS) patients under interferon beta 1-a subcutaneous treatment (IFN-beta) during 3 years of follow up.
|
30401571 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We aimed at investigating whether switching to intramuscular IFNB-1a injected once/week with the Avonex®Pen™ device improves treatment tolerability and quality of life in stable MS patients.
|
30763907 |
2019 |
|
Multiple Sclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Recombinant human interferon beta (rIFN-β) has long been used as a first-line treatment for multiple sclerosis (MS), and any attempt to develop a long-acting rIFN-β is desirable since only one pegylated version of long-acting rIFN-β-1a (Plegridy) is currently available in clinics.
|
30684504 |
2019 |